There is actually 70 m savings in operating expenses , so Mayne is operating both Nexstellis and TXMD at profit for the first time , so they are correct 14 m +ve contribution and international segment always making profit , hopefully they add more dermatology products from similar companies to use the existing sales force . Smart idea
Mayne Pharma sees strong sales growth in FY 2023, page-70
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.26 |
Change
-0.110(2.52%) |
Mkt cap ! $362.4M | |||
| Open | High | Low | Value | Volume |
| $4.36 | $4.36 | $4.25 | $253.7K | 59.12K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1090 | $4.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.26 | 2303 | 4 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |